Regeneron Pharmaceuticals (NASDAQ:REGN) Hits New 12-Month Low After Analyst Downgrade

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Get Free Report) reached a new 52-week low during trading on Thursday after UBS Group lowered their price target on the stock from $633.00 to $560.00. UBS Group currently has a neutral rating on the stock. Regeneron Pharmaceuticals traded as low as $476.49 and last traded at $483.19, with a volume of 332109 shares traded. The stock had previously closed at $484.93.

A number of other analysts have also issued reports on REGN. JPMorgan Chase & Co. lowered their target price on shares of Regeneron Pharmaceuticals from $1,100.00 to $1,000.00 and set an "overweight" rating for the company in a research note on Monday, March 31st. Wells Fargo & Company lowered shares of Regeneron Pharmaceuticals from an "overweight" rating to an "equal weight" rating and lowered their price objective for the stock from $700.00 to $580.00 in a research note on Friday, May 30th. Canaccord Genuity Group raised shares of Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, April 22nd. Cantor Fitzgerald started coverage on shares of Regeneron Pharmaceuticals in a research note on Tuesday, April 22nd. They issued an "overweight" rating and a $695.00 price objective for the company. Finally, Guggenheim reaffirmed a "buy" rating on shares of Regeneron Pharmaceuticals in a research note on Friday, May 30th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have given a buy rating and three have assigned a strong buy rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $844.48.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Rakuten Securities Inc. increased its holdings in Regeneron Pharmaceuticals by 62.5% in the 4th quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock worth $28,000 after buying an additional 15 shares during the period. TD Private Client Wealth LLC increased its holdings in Regeneron Pharmaceuticals by 9.6% in the 4th quarter. TD Private Client Wealth LLC now owns 171 shares of the biopharmaceutical company's stock worth $122,000 after buying an additional 15 shares during the period. Manchester Capital Management LLC increased its holdings in Regeneron Pharmaceuticals by 12.6% in the 4th quarter. Manchester Capital Management LLC now owns 161 shares of the biopharmaceutical company's stock worth $115,000 after buying an additional 18 shares during the period. Adirondack Trust Co. increased its holdings in Regeneron Pharmaceuticals by 4.2% in the 1st quarter. Adirondack Trust Co. now owns 451 shares of the biopharmaceutical company's stock worth $286,000 after buying an additional 18 shares during the period. Finally, Financial Perspectives Inc increased its holdings in Regeneron Pharmaceuticals by 10.9% in the 4th quarter. Financial Perspectives Inc now owns 193 shares of the biopharmaceutical company's stock worth $137,000 after buying an additional 19 shares during the period. Institutional investors and hedge funds own 83.31% of the company's stock.

Regeneron Pharmaceuticals Trading Down 0.4%

The company's fifty day moving average is $572.23 and its two-hundred day moving average is $659.43. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73. The company has a market cap of $52.15 billion, a price-to-earnings ratio of 12.62, a P/E/G ratio of 2.34 and a beta of 0.43.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share for the quarter, missing the consensus estimate of $8.83 by ($0.61). The business had revenue of $3.03 billion during the quarter, compared to analyst estimates of $3.40 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. Regeneron Pharmaceuticals's quarterly revenue was down 3.7% compared to the same quarter last year. During the same quarter last year, the company posted $9.55 EPS. On average, research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 6th. Stockholders of record on Tuesday, May 20th will be paid a dividend of $0.88 per share. The ex-dividend date of this dividend is Tuesday, May 20th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.73%. Regeneron Pharmaceuticals's payout ratio is 8.96%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.